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Abstract Barth syndrome (BTHS) is an X-linked mitochon-
drial defect characterised by dilated cardiomyopathy, neutro-
paenia and 3-methylglutaconic aciduria (3-MGCA). We
report on two affected brothers with c.646G>A (p.G216R)
TAZ gene mutations. The pathogenicity of the mutation, as
indicated by the structure-based functional analyses, was fur-
ther confirmed by abnormal monolysocardiolipin/cardiolipin
ratio in dry blood spots of the patients as well as the
occurrence of this mutation in another reported BTHS pro-
band. In both brothers, 2D-echocardiography revealed some
features of left ventricular noncompaction (LVNC) despite
marked differences in the course of the disease; the eldest
child presented with isolated cardiomyopathy from late infan-
cy, whereas the youngest showed severe lactic acidosis with-
out 3-MGCA during the neonatal period. An examination of
the patients’ fibroblast cultures revealed that extremely low
Communicated by: Eva Morava
Agnieszka Karkucinska-Wieckowska and Joanna Trubicka contributed
equally to this work.
Electronic supplementary material The online version of this article
(doi:10.1007/s10545-013-9584-4) contains supplementary material,
which is available to authorised users.
A. Karkucinska-Wieckowska :M. Pronicki : E. Czarnowska
Department of Pathology, The Children’s Memorial Health
Institute, Warsaw, Poland
J. Trubicka : E. Ciara
Department of Medical Genetics, The Children’s Memorial Health
Institute, Warsaw, Poland
B. Werner
Department of Pediatric Cardiology and General Pediatrics,
Medical University of Warsaw, Warsaw, Poland
K. Kokoszynska
Laboratory of Bioinformatics and Biostatistics, Maria
Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Roentgena 5,
02-781 Warsaw, Poland
M. Pajdowska
Department of Biochemistry and Experimental Medicine,
Children’s Memorial Health Institute, Warsaw, Poland
M. Lebiedzinska :M. R. Wieckowski
Nencki Institute of Experimental Biology, Warsaw, Poland
J. Sykut-Cegielska : E. Pronicka (*)
Department of Metabolic Diseases, The Children’s Memorial




Department of Cardiology, The Children’s Memorial Health
Institute, Warsaw, Poland
W. Jaron
Department of Surgery and Transplantation, The Children’s
Memorial Health Institute, Warsaw, Poland
A. Dobrzanska
Department of Neonatology, Pathology and Intensive Care,
The Children’s Memorial Health Institute,
Warsaw, Poland
J Inherit Metab Dis (2013) 36:929–937
DOI 10.1007/s10545-013-9584-4
mitochondrial membrane potentials (mtΔΨ about 50 % of the
control value) dominated other unspecific mitochondrial
changes detected (respiratory chain dysfunction, abnormal
ROS production and depressed antioxidant defense). 1) Our
studies confirm generalised mitochondrial dysfunction in the
skeletal muscle and the fibroblasts of BTHS patients, espe-
cially a severe impairment in the mtΔΨ and the inhibition of
complex V activity. It can be hypothesised that impaired
mtΔΨ and mitochondrial ATP synthase activity may contrib-
ute to episodes of cardiac arrhythmia that occurred unexpect-
edly in BTHS patients. 2) Severe lactic acidosis without 3-
methylglutaconic aciduria in male neonates as well as an
asymptomatic mild left ventricular noncompaction may char-
acterise the ranges of natural history of Barth syndrome.
Introduction
Barth syndrome (BTHS, OMIM 302060) is one of a large
group of “mitochondrial diseases” affecting boys (Barth et
al 1983; Barth et al 2004). The disorder is a rare inborn error
of metabolism. Although hundreds of cases have been iden-
tified worldwide, the Human Gene Mutation Database
(HGMD) includes only 54 patients for whom a genotype
has been established.
BTHS is caused by mutations in the tafazzin gene (TAZ)
and is inherited as an X-linked recessive trait (Barth et al
2004). Boys who are affected present with cardiopathy
(and myopathy), neutropaenia and 3-methylglutaconic
aciduria (3-MGCA) (Besley et al 1995; Chitayat et al 1992;
Christodoulou et al 1994).
The cardiac involvement in BTHS may include: left
ventricular (LV) dilation, hypertrophy and noncompaction
with varying degrees of congestive heart failure as well as
endocardial fibroelastosis. Although most patients have
dilated cardiomyopathy (DCM) the prominent LV trabe-
culations in half of the cases suggest a form of noncom-
paction cardiomyopathy (NCCM), named also a left
ventricular noncompaction (LVNC), and some have hy-
pertrophic cardiomyopathy (HCM). Cardiac transplantation
may be required in some BTHS patients (Spencer et al 2006;
Hanke et al 2012).
BTHS is the first identified genetic defect from a rapidly
expanding group of phospholipids defects (Lamari et al
2012), that directly affects cardiolipin (Houtkooper et al
2009a; b). Tafazzin is a component of the mitochondrial
membrane that is necessary for the proper functioning of
the electron transport chain (Brandner et al 2005; Claypool
2009; Haines2009).
Here, we present first Polish male siblings with BTHS
associated with a recurrent TAZ gene mutation and relatively
mild course of the disease, in which the studies of mito-
chondrial function directly confirmed severe impairment in
mitochondrial membrane potential (mtΔΨ) and the inhibi-
tion of complex V activity.
Materials
This investigation conforms to the principles outlined in the
Declaration of Helsinki, and the study protocol was approved
by The Bioethical Commission of The Children’s Memorial
Health Institute. Two patients with BTHS and seven fibroblast
cultures of patients with SCO2 (Pronicki et al 2010) and
SURF1 (Pronicki et al 2008) mutations were studied.
Patient 1
The boy was born at full term from a second pregnancy
(there was a maternal history of a single miscarriage). His
birth weight was 3.090 g, and his Apgar score after 5 min
was a 10. During infancy, feeding difficulties, growth retar-
dation (height 10th, weight corrected for height <3rd per-
centile) and delayed motor development were observed (he
sat at 8 mo, stood at 13 mo and started to walk at 24 mo).
At the age of 14 months, after a respiratory infection, a
cardiomyopathy occurred with severe heart failure (class IV
according to modified Ross Heart Failure classification).
After the treatment the patient's cardiac function progres-
sively improved. Since the age of two years no symptoms or
signs of heart failure have been found. ECG was without
signs of left ventricular hypertrophy. Slight cardiomegaly
was observed in roentgenogram. In echocardiography the
dimensions of left atrium and left ventricle diminished, the
diameter of left atrium was within normal limits and the left
ventricular diameter was on the upper border. The left ven-
tricular contractility markedly improved, SF was 30 %, EF
58 % (modified Simpson formula), and the moderate mitral
regurgitation was recorded. The ejection fraction reached
about 64 % at the age of 3.5 - 4 years and the treatment
with digoxin was stopped. In the next six following months
further reduction of the left ventricular dimensions was
observed and spironolacton was withdrawn.
Physical development has been delayed, always with
weight below the 3rd percentile.
Now, at the age of 9, the patient is asymptomatic, treated
only with captopril, and systematically followed by paediatric
cardiologists and metabolic paediatricians.
Patient 2
The younger brother of patient 1 (no data from the fetal period
is available) was healthy at birth (10 Apgar score after 5 min,
weight 3.240 g), but he developed hypotonia, tremor and
generalised oedema on the first day of life. Biochemical data
showed the following: severe metabolic acidosis (pH7.0,
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HCO3 5.0 mmol/L), markedly increased lactate in the plasma
(23.1 mmol/L) and urine, recurrent hypoglycaemia, rhabdo-
myolysis (CPK 7800 U/L, control below 171 U/L), liver
failure and an abnormal aminoacidogram (hyperalaninaemia,
hypertyrosinaemia and hypermetioninaemia). Generally the
baby demonstrated “severe neonatal lactic acidosis”. The
structure of the brain and cerebellum was normal, as deter-
mined through MRI. The ECG after birth was in normal
limits. Signs of right ventricular muscle hypertrophy were
described in echocardiography performed soon after birth,
which completely resolved within one month.
BTHSwas suspected due to the positive family history, and
pantothenate (a coenzyme A precursor) was administered as
reported previously (Ostman-Smith et al 1994). Transient low
serum biotinidase activity (3.68 u/mL, normal range 6-12
u/mL) were observed, and biotin was supplemented. The
patient’s clinical condition and biochemical status systemati-
cally improved, and he was discharged without treatment at
the age of 6 weeks. Recurrent skin Candida albicans infec-
tions were observed during the second year of life.
The boy never had any symptoms of heart failure therefore
the regular cardiological assessment was not carried out. At
age 3 years the boy is clinically asymptomatic. His weight and
height are at the lower control limit (10th percentile).
Methods
Morphological and biochemical methods
Open muscle biopsy was performed at the age of 14 days in
the younger brother (patient 2) and then in the older one
(patient 1) at the age of 6 years. Histological, histochemical
and spectrophotometric experiments on the muscle tissue
were performed as described (Bancroft and Gamble 2001;
Karczmarewicz et al 1997).
The muscle ultrastructure was evaluated under a JEM-
1010 electron microscope.
Isolation of mitochondria from muscle biopsies
Biopsy samples were stored at -80 °C and then defrosted
and cut into small pieces prior to resuspension in homoge-
nisation buffer. Skeletal muscles were homogenised on ice.
The homogenates were centrifuged twice at 1500 x g for
5 min. The supernatant was collected and centrifuged at
10,000 x g for 10 min. Finally, the mitochondrial pellets
were frozen at -80 °C until further use.
Blue native PAGE and in-gel activity assays
Blue native PAGE and an in-gel activity assay were per-
formed with muscle biopsies, as described (Van Coster et al
2001). Briefly, the mitochondria that were isolated from the
muscle biopsies were resuspended in aminocaproic acid
buffer (1.5 M 6-aminocaproic acid and 50 mM Bis–Tris,
pH7.0) and supplemented with n-dodecyl-beta-D-malto-
side at a final concentration of 1 %. The samples were
incubated on ice for 20 min and then centrifuged at
20,000×g for 15 min. The protein concentrations of the
supernatants containing the solubilised respiratory com-
plexes were determined according to Bradford’s method
using the Bio-Rad protein estimation kit. The supernatant
was supplemented with Serva Blue G (to a final concen-
tration of 0.5 %) and subjected to native electrophoresis
on an acrylamide gel gradient of 5–12 % in large format.
To visualise the activity of the mitochondrial ATPase
(complex V), the gel was incubated at 35 °C in a solution
containing 35 mM Tris-HCl, 270 mM glycine, 14 mM
MgSO4, 0.2 % Pb(NO3)2 and 8 mM ATP (pH7.8). To
visualise complex I activity, the gel was incubated at
35 °C in 3 mM Tris–HCl (pH7.4) containing 60 μM NADH
and 245 μM nitrotetrazolium blue (NBT). To visualise com-
plex II activity, the gel was incubated at 35 °C in 5 mM
phosphate buffer (pH7.4), 5 mM EDTA, 10 mM KCN,
50 mM succinate, 0.2 mM phenazine methosulphate and
245 μM NBT. To visualise complex IV activity, the gel
was incubated at 35 °C in 9 ml 50 mM phosphate buffer
(pH7.4) supplemented with 5 mg 3,3’-diamidobenzidine
tetrahydrochloride (DAB), 200 μg catalase, 10 mg cyto-
chrome c and 750 mg sucrose.
Western blot analysis of the mitochondrial respiratory chain
components
The levels of the individual subunits of the mitochondrial
respiratory chain were assessed using the Total OXPHOS
Human WB Antibody Cocktail (MitoSciences). SDS
lysates of the muscle biopsies (20 μg/line) were electro-
phoretically separated with a 10 % SDS-polyacrylamide
gel (BioRad). The proteins were transferred onto a PVDF
membrane using standard procedures. The membranes
were blocked with 2 % non-fat milk in TBS buffer con-
taining 0.01 % Tween 20 (Sigma Aldrich) for 1 h. The
membranes were immunoblotted with antibodies against
the subunits of the individual respiratory chain complexes
(1:5,000), followed by secondary HRP-conjugated antibodies
(1:5,000) (Santa Cruz).
Measurement of the mitochondrial membrane potential
(mtΔΨ)
The mitochondrial membrane potential (mtΔΨ) was mea-
sured using fluorescent indicators, as previously described
(Lebiedzinska et al 2010; Karkucinska-Wieckowska et al
2011). Fibroblasts were grown in 24-well plates, washed
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twice with PBS and incubated with 10 μM JC-1 in PBS
containing 5 mM glucose for 10 min at 37 °C. The cells
were then washed twice with PBS. Green and red fluo-
rescence were measured at wavelengths of 485 nm
excitation/520 nm emission and 535 nm excitation/635 nm
emission, respectively, using a microplate reader (Infinite
M200, Tecan, Austria).
The data obtained from the Tecan microplate reader were
calculated using Microsoft™ Excel 2005, and significance
was assessed with Student's t-test.
Molecular analysis
Genomic DNA was extracted from Guthrie cards through
incubation in the polymerase chain reaction (PCR) mix-
ture at 95 °C for 50 min. All of the exons of the TAZ
gene, including the flanking introns, were amplified with
PCR using seven intron-specific primer pairs. Detailed
PCR protocols and primer sequence information are
available upon request. Direct sequencing of the PCR
products was performed using a 3130 genetic analyser
(Applied Biosystems, Foster City, CA, USA). The
sequences were determined on both DNA strands from
at least two independent PCR products. The analysed
sequence fragments were compared with the TAZ cDNA
(GenBank RefSeq: NM_000116.3) and protein (GenBank
RefSeq: NP_000107.1) sequences using Mutation Sur-
veyor software version 3.30 (Softgenetics, PA). The po-
sition of the identified nucleotide change was determined
based on comparison with the reference sequence, with
the A of the ATG translation initiation codon designated
as nucleotide +1.
Structure-based functional analyses
Sequences that were homologous to the human TAZ
protein (NP_000107.1) were collected from the National
Centre for Biotechnology Information (NCBI) RefSeq
database. Selected sequences were aligned using the
ClustalW algorithm. Globular regions were predicted us-
ing GlobPlot. Transmembrane domains were determined
using TMHMM. The protein sequences were submitted
to the Meta-BASIC and Protein Structure Prediction
Meta-Server, which combines fold recognition and ho-
mology modelling methods. The secondary structure was
determined using PsiPred. The obtained results were
analysed with 3D-Jury, a consensus fold recognition
method. Based on these results, the structural templates
were mapped to the multiple sequence alignment of the
TAZ homologs. Homology models for each of the indi-
vidual domains were reconstructed using Modeller 9. The




The sequencing of the TAZ gene revealed a single-




Fig. 1 The DNA sequence of TAZ exon 8 with the c.646G>A
mutation in the proband (in the hemizygous stage), the proband’s
mother (in the heterozygous stage) and a healthy control
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substitution p.Gly216Arg in the hemizygous state in both
brothers and in the heterozygous state in their mother
(Fig. 1). A pedigree analysis of the family (Fig. 2) revealed
the deaths of at least three male relatives (late foetal, infan-
tile and child deaths) and at least nine potential female
carriers of the TAZ mutation.
Structure-based functional analyses
The identified TAZ gene mutation occurs in the splice site of
exon 8, which is highly conserved between species, suggest-
ing that this variant may disrupt the function of the encoded
protein (Supplementary Fig. 1). A detailed analysis of the
position of the mutated Gly216 showed that this residue is
facing the membrane, in which the N-terminal domain of the
protein is anchored (Fig. 3). The Gly216 mutation segregat-
ing within this family occurs within a TAZ specific loop
(position 216-232) that contains several conserved prolines
that maintain specific loop flexibility.
Biochemical abnormalities
Excretion of 3-MGCA in the urine was increased in all of
the measurements obtained, except for the first weeks of life
of the younger patient.
Neutropaenia was not present at the onset. Neutrophils
number fluctuated, and was normal in half of the measure-
ments ranging from 375 to 3680 and from 230 to 2320 per
mm3 (control above 1500 per mm3) respectively, in the
older and younger brother. In the older patient, at the age
of 4 years, an episode of severe neutropaenia was noted
during the course of pneumonia.
Hypocholesterolaemia and hypocarnitinaemia were not
evident The level of monolysocardiolipin/cardiolipin (MLCL/
CL) ratio measured at dry blood spots was increased in the
older and younger brothers, respectively to 1.20 and 0.50
(normal value 0 – 0.30). The analysis was performed in the
Laboratory Genetic Metabolic Disease, Academic Medical
Centre, Amsterdam.
Cardiological study
Multiple ECGs in patient 1 from the age of 14 months,
showed ST-T abnormalities in the form of flattening and/or
biphasic T (Supplementary Fig. 3). Similar biphasic Twaves
without signs of chamber hypertrophy were seen in patient 2
at the age of 3 years (Supplementary Fig. 4 and 5).
Fig. 2 Pedigree of the family
Fig. 3 The structural model of the TAZ protein rebuilt on PDB:1iuqA.
The key G216 residue is indicated with a magenta stick. The dark blue
element is an assumed transmembrane helix
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2D-echocardiography revealed some features of left ven-
tricular noncompaction (LVNC) in both affected brothers. In
patient 1 at the age of 8 years, two-layered myocardium was
seen with prominent trabeculations in the apex, with noncom-
pacted to compacted ratio about 1.6 (Supplementary Fig. 6).
In patient 2, at the age of 3 years, two-layered myocardium
was seen in systole with four trabeculations in the apical
region, and the noncompacted to compacted ratio about 1.0.
Holter monitoring (multiple) showed normal sinus rhythm,
normal conduction intervals, without evidence of arrhythmia
in all recordings in both affected brothers.
Mitochondrial study
In a study on BTHS fibroblasts, the most evident abnor-
mality was the impairment of mitochondrial membrane
potential, mtΔΨ. Interestingly, the mtΔΨ reduction was
nearly identical in the fibroblasts of both affected brothers
(40-50 % of control), and this reduction was more extreme
than the reduction observed in the fibroblasts of patients
with two other mitochondrial disorders (SCO2 gene or
SURF1 gene mutations). Control fibroblasts were included
as a reference (Fig. 4).
Other less specific changes in mitochondrial morphology
and function were also observed in the studied BTHS
patients. Muscle histochemistry in one of the patients
revealed moderate lipid accumulation, low COX activity
and a weak SDH reaction, which developed only after
prolonged incubation time (1.5 and 3 h). Relatively low
activity of the respiratory chain complex IV and II+III were
found by spectrophotometry of muscle homogenate. The
muscle electron microscopy showed polymorphic mito-
chondria of variable size (0.02-0.16 μm2), decreased dis-
tance between inner membrane and myelin-like structure in
mitochondrial matrix, and abundant glycogen and lipid
droplets in contact with the mitochondrion. The results of blue
native electrophoresis and an in-gel activity assay revealed a
decrease in the ATPase activity of complex V (Fig. 5). West-
ern blot analysis (Fig. 6) revealed more complex mitochon-
drial dysfunction represented by lower complex Vand I levels
in the two studied patients versus control.
Discussion
Although most of the known TAZ gene mutations are unique
for probands and their families (Cantlay et al 1999; Bione et
al 1996; Johnston et al 1997), the c.646G>A (p.G216R)
mutation detected in this family has been previously de-
scribed (Kuijpers et al 2004). The exchange of a small
amino acid for a positively charged residue (Gly216 to
Arg) in a region of TAZ specific loop is likely to influence
the negatively charged cardiolipins that are localised to the
mitochondrial membrane, resulting in failed cardiolipin bio-
synthesis and reduced ATP production. The pathogenicity of
the p.G216R mutation, as indicated by the structure-based
functional analyses, was further confirmed by observations
of an abnormal MLCL/CL ratio in the described family.
The necessity of expanding the indications for differen-
tial diagnosis of BTHS for a pregnancy loss (as in the
described family), and an idiopathic mitochondrial disease
has been recently highlighted by Steward et al (2010). Prior
experience with the first two Polish BTHS patients has
shown that strict compliance with the requirements of the
diagnostic triad for BTHS may delay a proper diagnosis
(Sweeney et al 2008; Werner et al 2011). In the younger
brother who had the initial diagnosis of “severe neonatal
lactic acidosis”, neither neutropaenia nor 3-MGCA was
observed in the neonatal period, as reported (Schmidt et al
2004). After recovery from severe life-threatening neonatal
disease, the boy did not show any cardiologic symptoms
until the age of 3 years. Except for the positive family
history and the presence of the TAZ gene mutation, little
laboratory evidence of BTHS existed. The symptoms of the
older brother are more evident (stunted growth and cardio-
myopathy) than in the younger brother but are still of only
moderate intensity. Neutropaenia occurred only cyclically
and was uncovered only when looked for on several occa-
sions. The increased excretion of 3-MGCA was the most
stable parameter of BTHS criteria triad in the described
boys. However at neonatal period, a search for 3-MGCA
in urine could be negative in affected patients. The increased
excretion of 3-MGCA was not found in repeated GC-MS
testing during the first three months of life of patient 2. Such
phenomenon had been previously reported in one BTHS
neonate (Schmidt et al 2004).
Clinical differences in the course of BTHS have been
described in the literature, even for patients that bear iden-
tical mutations. Because no phenotypic association has been
found among different types of mutations and any of the
Fig. 4 The mitochondrial membrane potential in the fibroblasts of the
two brothers with Barth syndrome (2 lines, n=4), control fibroblasts (4
lines, n=10), SCO2-deficient fibroblasts (3 lines, n=5) and SURF1-
deficient fibroblasts (4 lines, n=6). The data shown are the mean±SD,
*p<0.05 versus control
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clinical or laboratory abnormalities, it is likely that addition-
al factors (acquired or inherited) modify the BTHS pheno-
type in individual affected patients, including members of
the same family (Christodoulou et al 1994; Johnston et al
1997; Kelley et al 1991).
Isolated LVNC is frequently described in BTHS (Brandner
et al 2005; Chen et al 2002). Furthermore, Spencer et al (2006)
reported that many BTHS patients have qualitatively promi-
nent trabeculations of the left ventricle, and two independent
experts considered these patients to be in the left ventricular
noncompaction group, even though they had not met the
published criteria. Among the 30 patients with echocardio-
grams supporting this determination, only 16 (53 %) demon-
strated an abnormal morphology of the left ventricle with
increased trabeculations.
LVNC represents a wide spectrum of morphological and
clinical findings. 2D-echocardiography still is the method of
choice in the diagnosis of this cardiomyopathy (Engberding
et al 2007) and characteristic echocardiographic appearance
may help to differentiate LVNC from other forms of cardio-
myopathy like apical hypertrophic or dilated cardiomyopa-
thy in patients with impaired left ventricular systolic
function. However the echocardiographic criteria are still
controversial. The fundamental feature of the condition is
the presence of the two-layered myocardium: thin compact
outer layer and thick noncompact endocardial layer with
increased number of trabeculations and deep intertrabecular
recesses communicating with left ventricular cavity imag-
ined by colour Doppler. It is commonly known that two-
layered myocardium can be sometimes demonstrated in
healthy children and adults which can lead to misleading
diagnosis of LVNC. Therefore, a quantification of the non-
compacted to compacted ratio was implemented, for the first
time by Chin et al (1990), then Ischida et al (1990), Jenni et
al (2001) and others. There is no consensus in the literature
if the ratio should be measured at end diastole or end systole
neither of the cut-off value of it (1.4; 2.0; 2.3). In our centre
we perform the end-systolic measurement and for children
we use the cut-off value 1.4 therefore the older brother
fulfills the criteria of LVNC. The younger brother with the
ratio about 1.0 meets the criteria recently proposed by
Stollberger et al (2011). There is a broad discussion in the
literature on the redefinition of the diagnostic criteria. The
study of Saleeb et al (2012) demonstrated that the qualitative
diagnosis and quantitative measurements are poorly repro-
ducible between observers. Transesophageal echocardiogra-
phy, 3D real time and contrast echocardiography play a
complementary role in patients with poor quality of transtho-
racic images. The usefulness of cardiac magnetic resonance,
computed tomography and invasive left ventriculography was
documented in the small number of patients. All the men-
tioned methods could be helpful in the detailed diagnosis of
LVNC as well as left ventricular function assessment and
further studies on this issue are necessary.
In BTHS, repolarisation abnormalities predominantly in-
clude ST flattening or T-wave inversion (Ostman-Smith et al





Fig. 5 Blue native electrophoresis and a complex V in-gel activity
assay of the mitochondria isolated from the muscle biopsies of two
brothers with Barth syndrome. A significant decrease in the activity of
complex V is observed compared with the control muscle biopsy. P1,
older brother; P2, younger brother
Fig. 6 A western blot analysis shows the mitochondrial respiratory
chain composition in muscle biopsies of two brothers with Barth
syndrome. A decreased amount of complex V α subunit is observed
compared with a healthy control. The 20 kDa subunit of complex I was
detectable in the older patient upon prolonged exposure. Densitometry
analysis of the data is presented in Supplementary Fig. 2. P1: older
brother; P2: younger brother
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the development of T-wave abnormalities in the form of a
“camel’s hump” biphasic T-wave and progressive T-wave in-
version. These abnormalities were also seen in the presented
BTHS brothers.
The data from the literature show that despite their
currently reported good clinical condition, the boys in
this study are at risk for ventricular tachycardia, which
may lead to sudden cardiac death, and they require
close cardiac monitoring (Barth et al 2004; Spencer et
al 2005). The role of cardiolipin deficiency or altered
distribution of the mitochondrial membrane phospholi-
pids in the mechanism of arrhythmia has been considered
(Spencer et al 2005).
We previously found that the decrease in mtΔΨ was
less pronounced in an infant with fatal mitochondrial car-
diomyopathy (Lebiedzinska et al 2010) and a girl with a
MEGDEL association (Karkucinska-Wieckowska et al
2011) (70 % and 75 % of control, respectively). Moreover,
BTHS lymphoblasts showed reduced mtΔΨ, as indicated
with JC-1 probe measurements (Xu et al 2005). Similarly,
decreased mtΔΨ and a lower activity of the individual
respiratory chain complexes have also been reported by
Besley et al (1995).
Tafazzin deficiency in BTHS leads to a cardiolipin
remodelling defect (Houtkooper et al 2009a; Vrecken et al
2000) that affects the assembly and stability of supercom-
plexes of complex III and IV (and most likely also of
complex V) in the inner mitochondrial membrane. These
alterations result in the impairment of respiratory chain
activity (Brandner et al 2005; Arnold et al 1998; Schagger
and Pfeiffer 2000) and reduced ATP synthesis in BTHS
(Haines 2009). Our studies show that reduced mitochondrial
ATP synthase activity is accompanied by altered levels of its
α subunit (Fig. 6). Moreover, a decrease in ATP synthase
activity occurs not only with BTHS but also with other types
of 3-MGCA (Besley et al 1995; Sperl et al 2006; Wortmann
et al 2010).
Interestingly, we have previously observed increased
ROS production, alterations in antioxidant defence and an
increased level of protein carbonylation in BTHS fibroblasts
(Lebiedzinska et al 2010). To our knowledge, these findings
have not been previously reported. Thus, one may speculate
that the natural course of the disease can be influenced, for
example, by a background profile of antioxidant defence
capacity in an individual patient.
Summary
1) Our studies confirm generalised mitochondrial dys-
function in the skeletal muscle and the fibroblasts of
BTHS patients, especially a severe impairment in the
mitochondrial membrane potential and the inhibition
of complex V activity.
2) It can be hypothesised that impaired mtΔΨ and mitochon-
drial ATP synthase activity may contribute to episodes of
cardiac arrhythmia that occurred unexpectedly in BTHS
patients (Brown and O’Rourke 2010; Spencer et al 2005).
3) Severe lactic acidosis without 3-methylglutaconic acidu-
ria in male neonates as well as asymptomatic left ventric-
ular noncompaction at ECHO record may characterise a
range of natural history of Barth syndrome.
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